Adjuvant Endocrine Treatment of Early Breast Cancer

Hematology/Oncology Clinics of North America

Volumn 21, Issue 2, 2007, Pages 223-238

  Lønning, Per Eystein ^a  

^a Institute of Medicine   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; DROLOXIFENE; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GOSERELIN; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AMENORRHEA; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MONOTHERAPY; OSTEOPOROSIS; OVARY FUNCTION; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; VAGINAL DRYNESS;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENDOCRINE SYSTEM; FEMALE; HUMANS; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 34249063579     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.03.002     Document Type: Review

References (78)

1. Clarke M., Collins R., Davies C., et al. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 348 9036 (1996) 1189-1196
2. DelMastro L., Venturini M., Sertoli M.R., et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43 2 (1997) 183-190
3. Parulekar W.R., Day A.G., Ottaway J.A., et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCICCTG MA.5. J Clin Oncol 23 25 (2005) 6002-6008
4. Albain K., Green S., Ravdin P., et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup Trial 0100 (SWOG-8814). Proceeding of the American Society of Clinical Oncology 21 (2002) 37a
5. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
6. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
7. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
8. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
9. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
10. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 22 (2005) 5138-5147
11. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
12. Jakesz R., Hausmaninger H., Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20 24 (2002) 4621-4627
13. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20 24 (2002) 4628-4635
14. Harvey J.M., Clark G.M., Osborne C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 5 (1999) 1474-1481
15. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93 9 (2001) 684-690
16. Stewart H.J., Prescott R.J., and Forrest A.P.M. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 93 6 (2001) 456-462
17. Caleffi M., Fentiman I.S., Clark G.M., et al. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain. J Endocrinol 119 (1988) 335-339
18. Groom G.V., and Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol 70 (1976) 421-428
19. Decensi A., Robertson C., Viale G., et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95 11 (2003) 779-790
20. Buzdar A., Hayes D., El-Khoudary A., et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73 2 (2002) 161-175
21. Geisler J., Ekse D., Hösch S., et al. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 55 (1995) 193-195
22. Geisler J., Haarstad H., Gundersen S., et al. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol 146 (1995) 359-363
23. Helle S.I., Anker G., Tally M., et al. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 57 (1996) 167-171
24. Abrahamsen B., Vestergaard P., Rud B., et al. Ten-year absolute risk of osteoporotic fractures according to BMD T score at menopause: the Danish Osteoporosis Prevention Study. J Bone Miner Res 21 5 (2006) 796-800
25. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295 23 (2006) 2727-2741
26. Geisler J., and Lønning P.E. Aromatase inhibition-translation into a successful therapeutic approach. Clin Cancer Res 11 (2005) 2809-2821
27. Lønning P.E. Aromatase inhibitors in breast cancer. Endocr Relat Cancer 11 (2004) 179-189
28. Smith I.E., Dowsett M., Yap Y.S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced arnenorrhoea: caution and suggested guidelines. J Clin Oncol 24 16 (2006) 2444-2447
29. Burstein H.J., Mayer E., Partridge A.H., et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer 7 (2006) 158-161
30. Hargis J.B., and Nakajima S.T. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. Cancer Invest 24 2 (2006) 174-177
31. Al-Fadhli R., Sylvestre C., Buckett W., et al. A randomized trial of superovulation with two different doses of letrozole. Fertil Steril 85 1 (2006) 161-164
32. Baum M., Buzdar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
33. Lien E.A., Anker G., Lønning P.E., et al. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res 50 (1990) 5851-5857
34. Coombes R., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study: a randomised controlled trial. Lancet 369 (2007) 559-570
35. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCICCTG MA.17. J Natl Cancer Inst 97 17 (2005) 1262-1271
36. Punglia R.S., Kuntz K.M., Winer E.P., et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 23 22 (2005) 5178-5187
37. Cuzick J., Sasieni P., and Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer 94 4 (2006) 460-464
38. Fallowfield L.J., Bliss J.M., Porter L.S., et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24 6 (2006) 910-917
39. Kendall A., Dowsett M., Folkerd E., et al. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17 4 (2006) 584-587
40. Geisler J., Lundgren S., Berntsen H., et al. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83 8 (1998) 2687-2693
41. Jones A.L., Powles T.J., Law M., et al. Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol 10 10 (1992) 1547-1552
42. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy-the Women's Health Initiative randomized controlled trial. JAMA 291 14 (2004) 1701-1712
43. Nordenskjold B., Rosell J., Rutqvist L.E., et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 97 21 (2005) 1609-1610
44. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17 L). Ann Oncol 16 5 (2005) 707-715
45. Markopoulos C., Chrissochou M., Michailidou A., et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 16 8 (2005) 879-883
46. Lønning P.E., Geisler J., Krag L.E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 22 (2005) 5126-5137
47. Coleman R.E., and ATAC Trialists' Group. Effect of anastrozole on bone mineral density: 5-year results from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24 Suppl 18S (2006) 511
48. Lønning P.E. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 17 2 (2006) 217-225
49. Geisler J., Haynes B., Anker G., et al. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 20 (2002) 751-757
50. ®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74 (1996) 1286-1291
51. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4 (1998) 2089-2093
52. Lønning P.E. Pharmacology of new aromatase inhibitors. Breast 5 (1996) 202-208
53. Johannessen D.C., Engan T., di Salle E., et al. Endocrine and clinical effects of exemestane (PNU 15571), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3 (1997) 1101-1108
54. Lea O.A., Kvinnsland S., and Thorsen T. Improved measurement of androgen receptors in human breast cancer. Cancer Res 49 (1989) 7162-7167
55. Lønning P.E., and Lien E. Mechanisms of action of endocrine treatment in breast cancer. Critical Reviews in Oncology and Haematology 21 (1995) 158-193
56. Raisz L.G., Wiita B., Artis A., et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 81 1 (1996) 37-43
57. Goss P.E., Qi S., Josse R.G., et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 34 3 (2004) 384-392
58. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 22 (2005) 5108-5116
59. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 11 (2001) 1527-1532
60. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 30 (2005) 7512-7517
61. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
62. Eidne K.A., Flanagan C.A., and Millar R.P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229 (1985) 989-992
63. Taylor C.W., Green S., Dalton W.S., et al. A multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16 3 (1998) 994-999
64. Klijn J.G.M., Beex L.V.A.M., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92 11 (2000) 903-911
65. Klijn J.G.M., Blamey R.W., Boccardo F., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19 2 (2001) 343-353
66. Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 42 7 (2006) 895-904
67. Francis P., Fleming G., Nasi M., et al. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: the SOFT, TEXT, and PERCHE trials. Breast 12 Suppl 1 (2003) S44
68. Castiglione-Gertsch M., O'Neill A., Price K.N., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95 24 (2003) 1833-1846
69. Bartlett K., Eremin O., Hutcheon A., et al. On behalf of the Scottish Cancer Trial Breast Group and ICRF Breast Unit. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 341 (1993) 1293-1298
70. Boccardo F., Rubagotti A., Amoroso D., et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18 14 (2000) 2718-2727
71. Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39 12 (2003) 1711-1717
72. Petrek J.A., Naughton M.J., Case L.D., et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24 7 (2006) 1045-1051
73. Davidson N.E., O'Neill A.M., Vukov A.M., et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 23 25 (2005) 5973-5982
74. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21 6 (2003) 976-983
75. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352 22 (2005) 2302-2313
76. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 13 (2006) 2019-2027
77. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21 8 (2003) 1431-1439
78. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (2006) 1658-1667